HF
BCLI

HRT Financial’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

HRT Financial’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,022
Closed -$45K – 2531
2024
Q4 		$45K Buy
+20,022
New +$37K ﹤0.01% 2122
2021
Q4 		– Sell
-5,433
Closed -$268K – 3189
2021
Q3 		$268K Sell
5,433
-300
-5% -$15.8K ﹤0.01% 2489
2021
Q2 		$326K Buy
+5,733
New +$306K ﹤0.01% 2091
2021
Q1 		– Sell
-1,775
Closed -$120K – 2687
2020
Q4 		$120K Buy
+1,775
New +$242K ﹤0.01% 1610

Other funds holding BCLI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

HRT Financial's BCLI Position: Q1 2025 in Review

HRT Financial sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q1 2025, closing a stake of 20,022 shares — an estimated $45K sold.

HRT Financial first reported a position in BCLI in Q4 2020 and held it in 4 quarters. The position peaked at $326K in Q2 2021. 32 funds tracked by Wall St. Rank hold BCLI as of Q1 2025.

  • HRT Financial reported no remaining BRAINSTORM CELL THERAPUTC position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 20,022 BRAINSTORM CELL THERAPUTC shares in Q1 2025, an estimated $45K.
  • HRT Financial first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2020 and held it in 4 quarters.
  • HRT Financial's BRAINSTORM CELL THERAPUTC position peaked at $326K in Q2 2021.
  • 32 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.